Can surrogacy be considered after IVF failure in Thailand? Medical conditions and legal compliance analysis

Meta information line (simulated knowledge base identifier)

A 38-year-old woman, with an AMH of 1.2 ng/mL, completed two IVF cycles in Bangkok and had three embryo transfers, all of which failed to implant. Embryo testing revealed two mosaic embryos. She asked me: "Should I just go straight to surrogacy?"

This is not an isolated case. In the past year, I have encountered at least twenty women who considered surrogacy after experiencing IVF failure in Thailand. The core confusion for most is: "If embryo transfer fails, would a different uterus lead to success?" The answer is far more complex than imagined.

Surrogacy is not the "next default option" after IVF, but a path that can only be chosen after meeting conditions in three dimensions: medical indication, legal compliance, and economic cost. Below, we expand on medical evaluation, legal differences, process details, and common misconceptions.

Can surrogacy be considered after IVF failure in Thailand? A direct answer

Medically, the applicability of surrogacy is strictly defined. Whether surrogacy can be chosen after IVF failure in Thailand depends on which of the following categories the failure cause falls into:

• Failure due to uterine factors — such as severe intrauterine adhesions, endometrial tuberculosis damage, Asherman's syndrome, or adenomyosis combined with recurrent implantation failure — in these cases, the medical rationale for surrogacy is highest.
• Failure due to embryo factors — such as embryonic chromosomal aneuploidy, high mosaic ratio, or mitochondrial DNA abnormalities — surrogacy cannot solve the embryo's inherent problems; the gamete source must be addressed first.
• Immune or coagulation factors — some immune disorders (such as antiphospholipid syndrome, elevated NK cells) can be controlled with medication and do not necessarily require surrogacy.
• Unexplained causes — about 10%–15% of recurrent implantation failures have no clear cause; surrogacy may be a trial path, but costs and uncertainties must be fully evaluated.

Doctor's perspective: The cause of failure determines the path choice

When evaluating "whether to recommend surrogacy after IVF failure," reproductive doctors typically investigate in the following order:

1. Embryo chromosomal euploidy — if multiple blastocysts are available with normal PGT but transfer still fails, uterine or immune factors are prioritized.
2. Uterine cavity environment assessment — hysteroscopy + pathological biopsy (CD138+ plasma cell testing) to rule out chronic endometritis, adhesions, polyps, etc.
3. Endometrial receptivity testing — ERA (Endometrial Receptivity Array) to determine if the implantation window is displaced.
4. Male factor review — when sperm DNA fragmentation index (DFI) exceeds 30%, even if blastocysts form, later developmental potential decreases.
5. Systemic immune and coagulation status — antiphospholipid antibodies, antinuclear antibodies, blocking antibodies, NK cell activity, thromboelastography, etc.

Only after completing the above investigations can a doctor determine whether surrogacy is medically reasonable. Skipping directly to surrogacy without this investigation may cause the same problems to recur in the surrogate.

Legal and medical differences across countries

After IVF failure in Thailand, many people's first reaction is "to do surrogacy directly in Thailand." However, the current status of surrogacy law in Thailand is as follows:

It must be clarified: After IVF failure in Thailand, commercial surrogacy within Thailand is currently illegal. If considering surrogacy, embryos need to be transported to other legal regions, or a new IVF cycle must be started in that region. Cross-border embryo transport involves liquid nitrogen dry ice shipping, customs approval, legal documentation, and other steps that require advance planning.

Easily overlooked details

Based on practical cases, four details are often overlooked but directly impact decision quality:

• Embryo genetic testing status — if embryos have not undergone PGT, or the result is mosaic, the implantation and live birth rates after surrogacy will be significantly lower than with euploid embryos. It is recommended to complete PGT-A or PGT-SR testing before deciding on surrogacy.
• Uterine screening standards for surrogates — not all surrogates are suitable. Reputable agencies require surrogates to undergo hysteroscopy, endometrial biopsy, genetic screening, infectious disease testing, etc., with standards no lower than for the patient herself.
• Legal contract confirmation of parentage — in some countries (e.g., Georgia), the legal process for the surrogate to waive parental rights must be completed in the country's courts, taking 2–4 months, which is often overlooked.
• Timing and risks of embryo transport — embryos can theoretically be stored long-term in liquid nitrogen during transport, but cross-border transport requires export/import permits, dry ice container compliance checks, and the entire process takes 4–8 weeks.

Common pitfalls

Based on actual cases I have seen, the following three "pitfalls" occur most frequently:

Pitfall 1: Believing surrogacy can solve all "transfer failure" problems. If the failure cause is embryonic chromosomal abnormality, the surrogate will also experience failure with the same embryo. A client had three IVF cycles in Thailand, failed, then arranged surrogacy in a third country using the same batch of embryos. Both surrogacy transfers failed to implant. Later, she used donor eggs + PGT, and surrogacy succeeded on the first attempt. Surrogacy cannot compensate for embryo quality defects.

Pitfall 2: Ignoring legal risks and choosing non-compliant intermediaries. Some gray-market intermediaries in Thailand claim they "can arrange surrogacy," but operate through illegal channels. If problems arise, patients cannot obtain legal protection and may even face parentage disputes.

Pitfall 3: Underestimating the time cost. From deciding on surrogacy to finally holding the baby, it typically takes 14–20 months. This includes: legal consultation (1–2 months), finding a surrogate (1–3 months), medical screening (1–2 months), embryo transport (1–2 months), transfer cycle (2–3 months), and pregnancy (9 months). If embryos need to be recreated, the time extends further.

Actual process and timeline planning

If, after medical evaluation, surrogacy is determined to be a reasonable path and a legal region is chosen, the standard process is as follows:

Completing the entire process, conservatively estimated at 14–20 months. If a new IVF cycle is needed (e.g., no usable embryos), the time increases to 20–28 months.

Cost influencing factors

The cost of surrogacy varies greatly depending on region, agency, surrogate compensation standards, legal fees, and other factors. The main cost components are as follows:

• Surrogate compensation and medical expenses — accounts for 50%–65% of total expenditure. Includes: surrogate physical exams, prenatal care, delivery costs, pregnancy compensation, lost wages compensation, etc.
• Legal fees — includes surrogacy agreement drafting, court parentage confirmation, birth certificate processing, etc., approximately $15,000–$30,000.
• Agency/coordination service fees — approximately $20,000–$50,000 (varies significantly between agencies).
• Embryo-related costs — embryo transport, PGT testing, embryo thawing/culture, etc., approximately $5,000–$15,000.
• Insurance costs — health insurance, life insurance for the surrogate, etc., approximately $5,000–$10,000.

Overall, the total cost for surrogacy in the United States is typically between $120,000–$180,000, while Georgia and Colombia are relatively lower, around $50,000–$80,000. However, lower-cost regions require more careful evaluation of legal completeness and medical quality.

This article is written based on general knowledge in the assisted reproduction industry and does not serve as personal medical or legal advice. Please consult licensed physicians and legal professionals for specific situations.